JP2009506080A5 - - Google Patents

Download PDF

Info

Publication number
JP2009506080A5
JP2009506080A5 JP2008528306A JP2008528306A JP2009506080A5 JP 2009506080 A5 JP2009506080 A5 JP 2009506080A5 JP 2008528306 A JP2008528306 A JP 2008528306A JP 2008528306 A JP2008528306 A JP 2008528306A JP 2009506080 A5 JP2009506080 A5 JP 2009506080A5
Authority
JP
Japan
Prior art keywords
effective amount
therapeutic effect
receptor agonist
opioid receptor
antagonize
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008528306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009506080A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2006/001441 external-priority patent/WO2007025383A1/en
Publication of JP2009506080A publication Critical patent/JP2009506080A/ja
Publication of JP2009506080A5 publication Critical patent/JP2009506080A5/ja
Pending legal-status Critical Current

Links

JP2008528306A 2005-08-30 2006-08-30 超低用量のα−２−受容体アンタゴニストを用いる、オピオイド受容体アゴニストの治療作用の増強方法および／またはオピオイド受容体アゴニストに対する耐性の阻害方法もしくは逆転方法 Pending JP2009506080A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71254505P 2005-08-30 2005-08-30
US75395805P 2005-12-23 2005-12-23
PCT/CA2006/001441 WO2007025383A1 (en) 2005-08-30 2006-08-30 Potentiation of the therapeutic action of an opioid receptor agonist and/or inhibition or reversal of tolerance to an opioid receptoi agonists using an ultralow dose of an alpha-2 receptor antagonist

Publications (2)

Publication Number Publication Date
JP2009506080A JP2009506080A (ja) 2009-02-12
JP2009506080A5 true JP2009506080A5 (enExample) 2009-10-22

Family

ID=37808435

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008528306A Pending JP2009506080A (ja) 2005-08-30 2006-08-30 超低用量のα−２−受容体アンタゴニストを用いる、オピオイド受容体アゴニストの治療作用の増強方法および／またはオピオイド受容体アゴニストに対する耐性の阻害方法もしくは逆転方法

Country Status (7)

Country Link
US (1) US20070060501A1 (enExample)
EP (1) EP1942903A4 (enExample)
JP (1) JP2009506080A (enExample)
AU (1) AU2006287070A1 (enExample)
CA (1) CA2627158A1 (enExample)
IL (1) IL189869A0 (enExample)
WO (1) WO2007025383A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
ES2528669T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CA2600350C (en) * 2005-03-07 2015-02-10 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
WO2007057508A2 (en) * 2005-11-18 2007-05-24 Orion Corporation Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol
CA2657481A1 (en) * 2006-07-21 2008-01-24 Queen's University At Kingston Methods and therapies for potentiating a therapeutic action of an alpha- 2 adrenergic receptor agonist and inhibiting and/or reversing tolerance to alpha- 2 adrenergic receptor agonists
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
EP3263571B2 (en) 2007-03-29 2023-08-23 Progenics Pharmaceuticals, Inc. Crystal form of (r)-n-methylnaltrexone bromide and uses thereof
JP5461386B2 (ja) * 2007-03-29 2014-04-02 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 末梢オピオイド受容体アンタゴニストおよびその使用
MX2009010515A (es) * 2007-03-29 2009-10-19 Wyeth Corp Antagonistas del receptor opioide periferico y usos de los mismos.
US8471022B2 (en) * 2008-02-06 2013-06-25 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US8685995B2 (en) * 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8555875B2 (en) * 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US20110053913A1 (en) * 2009-06-25 2011-03-03 Khem Jhamandas Methods and Therapies for Alleviating Pain
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
WO2017120468A1 (en) * 2016-01-06 2017-07-13 Trevi Therapeutics, Inc. Therapeutic use of nalbuphine without aquaretic effects
CN112703000B (zh) 2018-07-23 2024-05-31 特雷维治疗股份有限公司 慢性咳嗽、呼吸急促和呼吸困难的治疗
EP3833346A4 (en) * 2018-08-08 2022-08-03 Torralva Medical Therapeutics LLC Compositions for opiate and opioid prevention and reversal, and methods of their use
AU2021206252A1 (en) 2020-01-10 2022-07-28 Trevi Therapeutics, Inc. Methods of administering nalbuphine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI81092C (fi) * 1986-05-15 1990-09-10 Farmos Oy Foerfarande foer framstaellning av terapeutiskt aktiva 4(5)-(2,3-dihydro-1h-inden-2-yl)-imidazolderivat.
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5855907A (en) * 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
DE19749724A1 (de) * 1997-11-11 1999-06-10 Gruenenthal Gmbh Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln
US6057368A (en) * 1998-08-05 2000-05-02 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
CA2424021A1 (en) * 2000-09-29 2002-04-04 Board Of Trustees Operating Michigan State University Catecholamine compositions and uses thereof
AU2003216954A1 (en) * 2002-03-29 2003-10-13 Orion Corporation Treatment of dependence and dependence related withdrawal symptoms

Similar Documents

Publication Publication Date Title
JP2009506080A5 (enExample)
FR25C1012I1 (fr) Posologie d'un agoniste du récepteur s1p
IL202752A0 (en) Il-23 receptor antagonists and uses thereof
BRPI0821683A2 (pt) Medicamento compreendendo um agonista parassimpatético e um antagonista simpatético ou agonista simpatético
PL2468290T3 (pl) Antagoniści aktywiny-ActRII do stosowania w leczeniu niedokrwistości
PL2054411T3 (pl) Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
IL189869A0 (en) Potentiation of the therapeutic action of an opioid receptor agonist and/or inhibition or reversal of tolerance to an opioid receptor agonists using an ultralow dose of an alpha-2 receptor antagonist
IL199680A0 (en) Piperidine gpcr agonists, compositions comprising the same, processes for producing ths same and uses thereof
NO343776B1 (no) Forbindelse som modulerer farmakokinetikkegenskaper til terapeutika, dens anvendelse i terapi og farmasøytisk sammensetning derav.
IL193467A0 (en) Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
MX2009009201A (es) Composicion farmaceutica.
EP2137191B8 (en) Peripheral opioid receptor antagonists and uses thereof
CL2007003265A1 (es) Compuestos derivados de 1h-piran[2,3-d]pirimidin-2,4,7-triona; y composicion farmaceutica, util para el tratamiento de sindrome metabolico, dislipidemia y enfermedades cardiovasculares entre otras.
IL192426A0 (en) Prokineticin 2 receptor antagonists
IL195071A (en) Antagonists / Agonists Cannabinoid Receptors and Medicines Containing Them
DK2081951T3 (da) Progesteron-receptorantagonister
HRP20150661T1 (en) Peripheral opioid receptor and antagonists and uses thereof
PL2238110T3 (pl) Pochodne 5,6-bisarylo-2-pirydyno-karboksamidu, ich wytwarzanie i ich zastosowanie terapeutyczne jako antagonistów receptora Urotensyny II
IL205608A0 (en) Triazole -substituted arylamide derivatives and their use as p2x3 and/or p2x2/3purinergic receptor antagonists
IL198780A0 (en) Pharmaceutical formulation comprising neurokinin antagonist
IL192270A0 (en) Substituted oxadiazole derivatives and their use as opioid receptor ligands
DK2121630T3 (da) Hurtigt dissocierende dopamin-2-receptor-antagonister
DE602005004011D1 (de) Hydroisoindolin-tachykininrezeptorantagonisten
CL2007002611A1 (es) Compuestos derivados de eter diarilico, antagonistas de los receptores opioides mu, kappa y delta; composicion farmaceutica; y uso para el tratamiento de la obesidad.
CL2008001795A1 (es) Uso de un antagonista par1 en el tratamiento de la fibrilacion atrial.